AbbVie Pushes Fed. Circ. To Resurrect Antibody Patent Spat
During oral arguments on Thursday, AbbVie claimed that a Massachusetts federal jury received “one-sided” instructions that downplayed Janssen Biotech's and its predecessor Centocor Biologics LLC's involvement in prior U.S. Patent and Trademark Office proceedings surrounding the two patents-in-suit, giving the companies a second shot at invalidating the antibody patents.
To view the full article, register now.